259 related articles for article (PubMed ID: 33457098)
21. Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma.
Slatnick LR; Jimeno A; Gore L; Macy ME
Drugs Today (Barc); 2021 Nov; 57(11):677-688. PubMed ID: 34821881
[TBL] [Abstract][Full Text] [Related]
22. Combined innate and adaptive immunotherapy overcomes resistance of immunologically cold syngeneic murine neuroblastoma to checkpoint inhibition.
Voeller J; Erbe AK; Slowinski J; Rasmussen K; Carlson PM; Hoefges A; VandenHeuvel S; Stuckwisch A; Wang X; Gillies SD; Patel RB; Farrel A; Rokita JL; Maris J; Hank JA; Morris ZS; Rakhmilevich AL; Sondel PM
J Immunother Cancer; 2019 Dec; 7(1):344. PubMed ID: 31810498
[TBL] [Abstract][Full Text] [Related]
23. Development of minimally invasive cancer immunotherapy using anti-disialoganglioside GD2 antibody-producing mesenchymal stem cells for a neuroblastoma mouse model.
Kambe K; Iguchi M; Higashi M; Yagyu S; Fumino S; Kishida T; Mazda O; Tajiri T
Pediatr Surg Int; 2022 Dec; 39(1):43. PubMed ID: 36484857
[TBL] [Abstract][Full Text] [Related]
24. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth.
Mujoo K; Cheresh DA; Yang HM; Reisfeld RA
Cancer Res; 1987 Feb; 47(4):1098-104. PubMed ID: 3100030
[TBL] [Abstract][Full Text] [Related]
25. New anti-GD2 monoclonal antibodies produced from gamma-interferon-treated neuroblastoma cells.
Gross N; Beck D; Portoukalian J; Favre S; Carrel S
Int J Cancer; 1989 Apr; 43(4):665-71. PubMed ID: 2467885
[TBL] [Abstract][Full Text] [Related]
26. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
[TBL] [Abstract][Full Text] [Related]
27. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
28. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse.
Raffaghello L; Marimpietri D; Pagnan G; Pastorino F; Cosimo E; Brignole C; Ponzoni M; Montaldo PG
Cancer Lett; 2003 Jul; 197(1-2):205-9. PubMed ID: 12880983
[TBL] [Abstract][Full Text] [Related]
29. Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy.
Ahmed M; Cheung NK
FEBS Lett; 2014 Jan; 588(2):288-97. PubMed ID: 24295643
[TBL] [Abstract][Full Text] [Related]
30. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.
Ye JN; Cheung NK
Int J Cancer; 1992 Jan; 50(2):197-201. PubMed ID: 1730513
[TBL] [Abstract][Full Text] [Related]
31. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
Fukuda M; Horibe K; Furukawa K
Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
[TBL] [Abstract][Full Text] [Related]
32. Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow.
Lode HN; Xiang R; Varki NM; Dolman CS; Gillies SD; Reisfeld RA
J Natl Cancer Inst; 1997 Nov; 89(21):1586-94. PubMed ID: 9362156
[TBL] [Abstract][Full Text] [Related]
33. Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro.
Kawashima I; Tada N; Fujimori T; Tai T
J Biochem; 1990 Jul; 108(1):109-15. PubMed ID: 2121721
[TBL] [Abstract][Full Text] [Related]
34. Reduction of CD11b
Siebert N; Zumpe M; von Lojewski L; Troschke-Meurer S; Marx M; Lode HN
Oncoimmunology; 2020 Oct; 9(1):1836768. PubMed ID: 33150046
[TBL] [Abstract][Full Text] [Related]
35. Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma.
Cabral J; Fernandez EI; Toy B; Secola R
Paediatr Drugs; 2023 Jan; 25(1):13-25. PubMed ID: 36434427
[TBL] [Abstract][Full Text] [Related]
36. A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Prapa M; Caldrer S; Spano C; Bestagno M; Golinelli G; Grisendi G; Petrachi T; Conte P; Horwitz EM; Campana D; Paolucci P; Dominici M
Oncotarget; 2015 Sep; 6(28):24884-94. PubMed ID: 26298772
[TBL] [Abstract][Full Text] [Related]
37. Positron Emission Tomography Detects
Butch ER; Mead PE; Amador Diaz V; Tillman H; Stewart E; Mishra JK; Kim J; Bahrami A; Dearling JLJ; Packard AB; Stoddard SV; Vāvere AL; Han Y; Shulkin BL; Snyder SE
Cancer Res; 2019 Jun; 79(12):3112-3124. PubMed ID: 31015228
[TBL] [Abstract][Full Text] [Related]
38. Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.
Mora J
Expert Rev Clin Pharmacol; 2016; 9(5):647-53. PubMed ID: 26934530
[TBL] [Abstract][Full Text] [Related]
39. A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.
Alvarez-Rueda N; Desselle A; Cochonneau D; Chaumette T; Clemenceau B; Leprieur S; Bougras G; Supiot S; Mussini JM; Barbet J; Saba J; Paris F; Aubry J; Birklé S
PLoS One; 2011; 6(9):e25220. PubMed ID: 21966461
[TBL] [Abstract][Full Text] [Related]
40. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).
Moutel S; Birkle S; Laurence V; Michon J; Fridman WH; Aubry J; Teillaud JL
Hybridoma; 1997 Aug; 16(4):335-46. PubMed ID: 9309424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]